What is the efficacy of moderate-intensity and high-intensity statin therapy in patients with risk-enhancing factors?
The efficacy of moderate- and high-intensity statin therapy in patients with risk-enhancing factors such as chronic inflammatory disease, chronic kidney disease, and metabolic syndrome is well established. Moderate-intensity statins have been found to reduce the risk of cardiovascular events, such as heart attack and stroke, by 25-35%, while high-intensity statins reduce risk by 35-45%. Furthermore, studies have demonstrated that the benefits of statin therapy may be further enhanced when combined with other risk-reduction strategies, such as lifestyle modifications, antiplatelet therapy, and blood pressure control.